Bayer announced positive topline results from the phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital that evaluated the investigational PET/CT radiotracer I 124 ...
I 124 evuzamitide is an investigational PET radiotracer–a radioactive diagnostic imaging agent injected into the body before ...
Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results